脂肪生成
脂肪变性
酒精性脂肪肝
脂肪肝
酒精性肝病
肝损伤
化学
内科学
内分泌学
脂肪酸合成
硬脂酰辅酶A去饱和酶
乙醇
脂肪酸
脂质代谢
生物化学
生物
医学
疾病
肝硬化
基因表达
基因
作者
Mohamed Amine Lounis,Quentin Escoula,Cathy Veillette,Karl‐F. Bergeron,James M. Ntambi,Cathérine Mounier
标识
DOI:10.1016/j.bbalip.2016.07.012
摘要
Stearoyl-CoA desaturase 1 (SCD1) is a delta-9 fatty acid desaturase that catalyzes the synthesis of mono-unsaturated fatty acids (MUFA). SCD1 is a critical control point regulating hepatic lipid synthesis and β-oxidation. Scd1 KO mice are resistant to the development of diet-induced non-alcoholic fatty liver disease (NAFLD). Using a chronic-binge protocol of ethanol-mediated liver injury, we aimed to determine if these KO mice are also resistant to the development of alcoholic fatty liver disease (AFLD). Mice fed a low-fat diet (especially low in MUFA) containing 5% ethanol for 10 days, followed by a single ethanol (5 g/kg) gavage, developed severe liver injury manifesting as hepatic steatosis. This was associated with an increase in de novo lipogenesis and inflammation. Using this model, we show that Scd1 KO mice are resistant to the development of AFLD. Scd1 KO mice do not show accumulation of hepatic triglycerides, activation of de novo lipogenesis nor elevation of cytokines or other pro-inflammatory markers. Incubating HepG2 cells with a SCD1 inhibitor induced a similar resistance to the effect of ethanol, confirming a role for SCD1 activity in mediating ethanol-induced hepatic injury. Taken together, our study shows that SCD1 is a key player in the development of AFLD and associated deleterious effects, and suggests SCD1 inhibition as a therapeutic option for the treatment of this hepatic disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI